Clinical trial · Observational
Clinical and Genomic Registry of MDS in Asia
Clinical and Genomic Registry of Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukaemia (AML) in Asia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myelodysplastic syndrome (MDS) is a group of clonal haematopoietic stem cell disorders characterized by ineffective haematopoiesis leading to cytopenia, with a significant risk of progression to acute myeloid leukaemia (AML). Progression to AML and resistance to hypomethylating agents (HMA) are important unmet clinical needs. The pathophysiology of MDS and its progression to AML involve cytogenetic, genetic and epigenetic aberrations, and hence better understanding of the molecular landscape of MDS has important clinical implications. Also, future treatment strategies for MDS may involve exploitation of genetic information in designing more effective therapy encompassing single agents or combinatorial approaches. The proposed cohort study aims to establish a registry of clinical and genomic registry of MDS and secondary AML in Asian patients, which allows the establishment of the mutational profile of patients and prognostic model for survival, as well as exploration of treatment strategies and prediction for treatment response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Time to progression to secondary AML
- timeFrame
- 60 months
- measure
- Overall survival
- timeFrame
- 60 months
- measure
- Progression-free survival
- timeFrame
- 60 months
Secondary outcomes (2)
- measure
- Time to first response to hypomethylating agent treatment
- timeFrame
- 60 months
- measure
- Best overall response to hypomethylating agent treatment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subject is an adult at the time of diagnosis of MDS. An adult is a person who has attained the legally defined age in accordance with local law. 2. Both biological parents and all four biological grandparents of the subject are the original people of the Far East, Southeast Asia, or the Indian subcontinent. 3. Subject was diagnosed with one of the following disorders according to the World Health Organization (WHO) classification criteria 2016: 1. Myelodysplastic syndrome (MDS) 2. Chronic myelomonocytic leukaemia (CMML) 3. MDS/ Myeloproliferative neoplasm (MPN) with ring sideroblasts and thrombocytosis (MPN-RS-T) 4. MDS/MPN unclassifiable 4. In prospective and partial prospective/retrospective case, subject has provided a signed written informed consent of this study. In retrospective case, subject has previously provided a signed written informed consent on: 1. voluntary provision of his/her data, and 2. voluntary provision of archived/remaining specimens for genetic analysis, and 3. authorizing storage and usage of archived/remaining specimens for any further analysis Exclusion Criteria: 1. Subject was diagnosed with acute myeloid leukaemia under the WHO classification criteria 2016 2. Subject was diagnosed with myeloproliferative neoplasms under the WHO classification criteria 2016
References
Publications (0)
Data not yet available